Incyte Corporation (LON:0J9P)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 14.60B +69.8% |
| Revenue (ttm) | 4.06B +21.5% |
| Net Income | 1.08B +6,631.4% |
| EPS | 5.35 +7,175.4% |
| Shares Out | n/a |
| PE Ratio | 13.47 |
| Forward PE | 12.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 669 |
| Average Volume | 992 |
| Open | 101.59 |
| Previous Close | 100.23 |
| Day's Range | 97.22 - 101.59 |
| 52-Week Range | 59.76 - 112.60 |
| Beta | 0.80 |
| RSI | 54.46 |
| Earnings Date | Apr 28, 2026 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial numbers in USD Financial StatementsNews
Incyte Transcript: Bank of America Global Healthcare Conference 2026
Leadership emphasized a strong financial position and a clear post-2029 growth strategy, with Jakafi and OPZELURA driving near-term performance. Pipeline assets like POVO and mCALR are advancing, and key data readouts are expected at major conferences.
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress.
Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial
Incyte (INCY) announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura cream in adults with moderate atopic dermatitis who had an inadequate…
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte gets orphan designation for treatment of pancreatic cancer
Incyte (INCY) Corporation was granted FDA orphan designation for a treatment of pancreatic cancer, according to a post to the agency’s website.
Incyte announces FDA approval of Jakari XR
Incyte (INCY) announced that the U.S. Food and Drug Administration has approved Jakafi XR extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis; adults wit...
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatmen...
Incyte price target raised to $90 from $84 at Oppenheimer
Oppenheimer raised the firm’s price target on Incyte (INCY) to $90 from $84 and keeps a Perform rating on the shares. The firm notes the company reported Q1 results boasting…
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences.
Incyte price target raised to $123 from $120 at Stifel
Stifel raised the firm’s price target on Incyte (INCY) to $123 from $120 and keeps a Buy rating on the shares.
Incyte price target raised to $124 from $121 at BofA
BofA raised the firm’s price target on Incyte (INCY) to $124 from $121 and keeps a Buy rating on the shares. The Q1 report showed typical seasonality, but FY26 guidance…
Incyte beats first-quarter estimates on strong demand for cancer drugs
Drugmaker Incyte beat analysts' estimates for first-quarter profit and revenue on Tuesday, partly helped by strong demand for its cancer treatments, including Jakafi and Minjuvi.
Incyte Earnings Call Transcript: Q1 2026
Q1 2026 saw 20% net sales growth and strong performance across all segments, with robust pipeline progress and new leadership appointments. Full-year guidance was reaffirmed, and multiple late-stage regulatory and clinical milestones were achieved.
Incyte sees FY26 revenue $4.77B-$4.94B, consensus $5.57B
Sees FY26 Jakafi net sales $3.22B-$3.27B, Opzelura net sales $750M-$790M
Incyte appoints Suketu Upadhyay as CFO
Incyte (INCY) announces the appointment of Suketu Upadhyay as Executive Vice President and Chief Financial Officer, CFO, effective May 4, 2026. In his new role, Upadhyay will serve as a…
Incyte reports Q1 EPS $1.81, consensus $1.34
Reports Q1 revenue $1.27B, consensus $1.22B. “Our first quarter represented a strong start to 2026, driven by 20% year-over-year net sales growth and strong commercial execution,” said Bill Meury, Chi...
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates.
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer.
Incyte to announce full results from Phase 3 tafasitamab study at ASCO
Incyte (INCY) announced that full results from the Phase 3 pivotal study evaluating tafasitamab in first-line diffuse large b-cell lymphoma will be featured as an oral presentation at the 2026…
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO26--Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--1Q Alert.
Incyte price target raised to $95 from $92 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Incyte (INCY) to $95 from $92 and keeps a Sector Perform rating on the shares as part of the…
Incyte announces new 54-week data on safety, efficacy of povorcitinib
Incyte (INCY) announced 54-week data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program...
Incyte's skin disease drug shows long-term symptom relief in late-stage trials
Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.